Dupont Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Dupont Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,426	Closed	-$276K	–	1816
2021 Q1	$276K	Sell	2,426 -498	-17%	-$67.8K	0.01%	1175
2020 Q4	$405K	Sell	2,924 -219	-7%	-$26K	0.01%	922
2020 Q3	$258K	Buy	+3,143	New	+$261K	0.01%	1029
2016 Q2	–	Sell	-7,292	Closed	-$462K	–	701
2016 Q1	$462K	Hold	7,292	–	–	0.01%	556
2015 Q4	$818K	Buy	+7,292	New	+$729K	0.02%	507

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dupont Capital Management's RARE Position: Q2 2021 in Review

Dupont Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2021, closing a stake of 2,426 shares — an estimated $276K sold.

Dupont Capital Management first reported a position in RARE in Q4 2015 and held it in 5 quarters. The position peaked at $818K in Q4 2015. 241 funds tracked by Wall St. Rank hold RARE as of Q2 2021.

Dupont Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2021 after selling out during the quarter.
Dupont Capital Management sold 2,426 Ultragenyx Pharmaceutical shares in Q2 2021, an estimated $276K.
Dupont Capital Management first reported a position in Ultragenyx Pharmaceutical in Q4 2015 and held it in 5 quarters.
Dupont Capital Management's Ultragenyx Pharmaceutical position peaked at $818K in Q4 2015.
241 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2021.

Based on Dupont Capital Management's 13F filing for Q2 2021, filed 30 Jul 2021.